Life Technologies
Life Technologies is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Life Technologies.
Life Technologies is a company.
Key people at Life Technologies.
Life Technologies Corporation was a leading biotechnology company specializing in genetic analysis, molecular biology research, cellular analysis, and diagnostic tools, serving pharmaceutical companies, biotech firms, academic institutions, government agencies, and clinical labs across more than 180 countries.[2][5] Headquartered in Carlsbad, California, it offered products like DNA sequencing systems, polymerase chain reaction (PCR) systems, reagents, cell culture media, and laboratory automation equipment, generating over 70% of revenue from essential consumables that supported critical lab workflows.[2][5] The company achieved $3-4 billion in annual revenue by 2013 with 9,500 employees globally before its $13.6 billion acquisition by Thermo Fisher Scientific in 2014.[2][4]
Life Technologies traces its roots to 1962 with the founding of Grand Island Biological Company (GIBCO) in New York, a key supplier of cell-growth media and enzymes for recombinant DNA work.[1][2][6] The original Life Technologies formed in 1983 via the merger of GIBCO (a Dexter Corp. subsidiary with $77 million in 1982 sales) and Bethesda Research Laboratories, going public in 1986 as a top provider of sera, enzymes, and biological products.[1][3] Invitrogen, started in an Encinitas garage by Lyle Turner, Joe Fernandez, and William McConnell, acquired the original Life Technologies in 2000 and discontinued the name.[1][2][4] Under CEO Greg Lucier (recruited from GE in 2003), Invitrogen turned around, expanding globally and becoming the #1 life sciences reagents company.[4] The modern Life Technologies revived in November 2008 through Invitrogen's $6.7 billion merger with Applied Biosystems, trading as LIFE on NASDAQ with $3 billion in sales and a focus on integrated solutions.[1][2][4][5]
Life Technologies rode the genomics and molecular diagnostics boom, capitalizing on recombinant DNA, PCR, and next-gen sequencing trends that transformed research, drug discovery, and clinical testing.[1][2][5] Its timing aligned with post-genome project demands for scalable tools, enabling pharma/biotech to accelerate genetic analysis amid rising personalized medicine needs.[5] Market forces like global lab expansion (operations in 180+ countries) and regulatory wins (e.g., 1989 FDA approval for HPV test projected at $50M/year potential) favored its growth, while acquisitions filled gaps in diagnostics and bioinformatics.[1][3] It influenced the ecosystem by consolidating fragmented tools into integrated platforms, boosting efficiency for 9,500-employee operations and setting standards in consumables that labs couldn't cut.[4][5]
Post-2014 acquisition, Life Technologies' technologies integrated into Thermo Fisher, amplifying capabilities in sequencing, diagnostics, and global research markets amid ongoing genomics advances like CRISPR and AI-driven analysis.[2] Trends such as regenerative medicine, single-cell sequencing, and expanded clinical applications will shape its legacy, with Thermo leveraging the portfolio for sustained dominance. Its influence endures as a foundational player, evolving from garage origins to powering modern biotech breakthroughs that redefine life sciences.
Key people at Life Technologies.
